WO2010090613A1 - Composition pharmaceutique combinée sous une forme posologique unique - Google Patents

Composition pharmaceutique combinée sous une forme posologique unique Download PDF

Info

Publication number
WO2010090613A1
WO2010090613A1 PCT/TR2010/000024 TR2010000024W WO2010090613A1 WO 2010090613 A1 WO2010090613 A1 WO 2010090613A1 TR 2010000024 W TR2010000024 W TR 2010000024W WO 2010090613 A1 WO2010090613 A1 WO 2010090613A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
sodium
range
weight
composition according
Prior art date
Application number
PCT/TR2010/000024
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2010090613A1 publication Critical patent/WO2010090613A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • This invention is directed to a stable combined pharmaceutical composition in a single dosage form so as to enhance the patient's treatment compliance and hence the success of the treatment.
  • the present invention provides an effective combination for the prevention and/or treatment and/ or supplement of diseases and conditions associated with the abnormal bone resorption.
  • the effect caused by the combination prepared according to the present invention as named as “desired effect” thoughout this document.
  • the combination of the present invention includes a calcium salt, vitamin-D and alendronate or pharmaceutically acceptable salt, derivative or hydrate thereof.
  • Alendronic acid is a bisphosphonate which has a chemical name of sodium [4-amino-l- hydroxybutylidene) biphosphonic acid (Formula I).
  • Alendronic acid is firstly disclosed in patent numbered US4705651 A. In this patent, manufacturing processes and the usage of alendronic acid in osteopathy treatment are included.
  • alendronate is a second generation diphosphonate, it is also the first drug of its general group which is capable of the reinforcing of the bone as well as inhibiting the bone loss.
  • Alendronate is a biphosphonate which connects to hydroxyapatite in the bone and inhibits osteoclast (a kind of bone cell which destroys bone tissue by destroying bone matrix) mediated bone resorption. Bone resorption occurs by ruffled edges of osteoclasts in contact with the bone which are capable of making resorption. Alendronate inhibits the resorption by localizing specially under the resorption area of osteoclasts. In time, normal bone tissues which are produced by osteoblasts plank down onto alendronate.
  • alendronate continues until it sinks inside the matrix where it shows no activity. However, alendronate will be connected to hydroxyapatite for years. Alendronate shoud be used continually to maintain the octeoclast inhibition on newly formed resorption surface.
  • Alendronate decreases the turnover of the bone. It increases the mass of bone wherein the bone formation exceeds the bone resorption. It also decreases the direct resorption of bone in Paget disease which is a progressive and idiopathic disease wherein the bone metabolism is accelerated and re-shaped. After the six months treatment, deformed bone is transformed into the normal bone structure. It sharply increases the bone mineral density in postmenopausal osteoporosis which is characterized with progressive loss of bone causing increase in fragility of bone mass. This increases in bone mass can be seen in spine and hip after three months of treatment After a year of treament, bone return back to its normal structure by means of both structure and the mineral content.
  • Vitamin D is a group of fat-soluble prohormones, the two major forms of which are vitamin D 2 (or ergocalciferol) and vitamin D 3 (or cholecalciferol) .
  • Vitamin D3 is a form of vitamin D with the chemical name of (3 ⁇ ,5Z,7E)-9, 10-secocholesta-5,7, 10( 19)-trien-3 -ol (Formul II).
  • Vitamin D3 is a form of Vitamin D that is synthesized in human body naturally. Vitamin D3 is occured naturally in the mammal skin from 7-dehydrocholesterol under the action of UV light. It can be partially provided by animal products. Vitamin D3 undergoes biotransformation in kidney and liver and turn into its active form of 1,25-dihydroxycholecalciferol ( [1,25-(OH) 2 D 3 ] veya calcitriol ).
  • Calcium is the chemical element with the symbol "Ca”. It is the most abundant mineral found in the human body. 99% of body calcium is found in bone tissue. It plays an important role on bone structure and muscle contractions. The blood coagulation, neural transmission and the provision of electrical conduction in the heart depends on calcium. Parathyroid hormone, vitamin D, calcitonin, glucocorticoids can affect the balance of calcium and magnesium.
  • Calcium and its salts are used for treatment or prophylaxis of calcium deficiency.
  • Calcium can be administered by oral route in carbonate, chloride, citrate, glubionate, gluceptate, gluconate, lactate, or phosphate salt forms; and it can be administered by parenteral route in acetate, chloride, gluceptate, gluconate, and glycerophosphate / lactate salt forms.
  • Minimum daily requirement of calcium in the postmenopausal women is 1500 mg. In the premenopausal women, this amount is 1000 mg. This indicates that in the in the post menopausal period a woman needs at least 500 mg / day of additional calcium supplementation. Vitamin D is required for absorption of calcium. It was determined that vitamin D deficiency and osteoporosis that develops as a result of this is a risk factor for falls and fractures. In the postmenopausal women, due to vitamin D deficiency, calcium absoiption is reduced. Various clinical studies have showed that daily calcium and vitamin D intake in men, just like in women, is lower than the recommended dose. This increases the probability of ratio of diseases (osteoporosis, osteomalacia, etc.) originating from vitamin D and calcium deficiency in adults of advanced age. Therefore, attention to dietary factors, as well as the use of various drugs supplements are also recommended.
  • US20050261250 Al discloses a pharmaceutical composition which comprises a biphosphonate or pharmaceutically acceptable salts, derivatives or hydrates or a mixture thereof and a vitamin D compound.
  • the patent numbered WO2005027921 Al describes a pharmaceutical composition which includes 2-methylene-19-nor-20(S)- l ⁇ ,25-dihydroxyvitamin D3 and a biphosphonate.
  • WO9906051 Al a pharmaceutical composition which is characterized in that it comprises a binding agent chosen in the group consisting of propylene glycol, a polyethylene glycol with a molecular weight between 300 and 1500, liquid paraffin or silicone oil and that the Vitamin D is present at the rate of 1 - 2 g of calcium for 500 1000 LU. of Vitamin D. has been described.
  • Patent numbered EP0969849 Bl describes pharmaceutical preparations containing a combination of an active form of vitamin D3 and tri calcium phosphate.
  • a bone mineral supplement which comprises calcium in the form of calcium citrate maleate in. the range of 100-1000 mg (on an elemental basis), and vitamin D wherein said vitamin D is administered as its biologically active metabolites and precursors selected from l ⁇ , 25- (OH) 2 vitamin D; 25 OH vitamin D, l ⁇ OH vitamin D 2 veya D 3 , or analogues of the dihydroxy compound in amounts equivalent to 0.60-30 ⁇ g vitamin D has been described.
  • a complicated dose regime, especially multiple drug use in several times a day is one of the most significant factor to prevent the patient's complience to treatment.
  • the patient compliance and therefore the success of treatment will be higher if the treatment regimen is much simpler.
  • the combination of the active ingredients in a single dosage form will simplify treatment and increase patient's complience to treatment[Blonde L. Compliance and Persistence With Medication Therapy. Managed Care (2000). Volume 9, Number 9; archives.who.int/icium/icium2004/resources/ppt/AC016.ppt.].
  • the negative impact of taking multiple drug on patients will also be eliminated by the use of a combined medication in the form of a single dosage form.
  • the present invention is directed to obtain a triple combination of alendronate (or pharmaceutically acceptable salts, derivatives or hydrates thereof), a calcium salt and vitamin D in a single dosage form so as to increase patient complience to the treatment and thus the treatment success.
  • the invention is characterized in that alendronate (or pharmaceutically acceptable salts, derivatives or hydrates thereof), a calcium salt and pharmaceutically acceptable, non-toxic and therapeutic amount of vitamin D are combined in a single dosage form to achieve desired effect by providing a suitable formulation of these three active agents.
  • formulations containing vitamin D are faced with stability problems because vitamin D tends to degrade upon exposure to heat, light, air, moisture, oxidizing agents or when exposed to an environment with acidic pH. This condition brings along the necessity of the selection of suitable excipients so as to ensure stability of vitamin D in tablet.
  • the present invention provides a stabilized pharmaceutical composition wherein alendronate (or pharmaceutically acceptable salts, derivatives or hydrates thereof), a calcium salt and vitamin D are combined in a single dosage form so as to obtain desired effect starting from increasing patient's compliance and thus the success of the treatment.
  • the pharmaceutical preparations of the present invention may include at least one stabilizing agent to ensure stability of vitamin D.
  • the present invention relates to a pharmaceutical composition for use in the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or used as a supplement characterized in that the pharmaceutical composition comprises therapeutically effective amount of alendronate or pharmaceutically acceptable salt, derivative or hydrate thereof, therapeutically effective amount of a calcium salt and therapeutically effective amount of vitamin D combined in a single dosage form.
  • the present invention provides a stabilized pharmaceutical composition in a single dosage form which comprises alendronate or pharmaceutically acceptable salt, derivative or hydrates thereof, a calcium salt and vitamin D to increase patient compliance and thus the success of treatment and to achieve the desired effect.
  • the formulations in a single dosage form comprise a certain proportion of alendronate (or pharmaceutically acceptable salt, derivative or hydrate thereof), a certain proportion of calcium salts and a certain proportion of vitamin D, and optionally one or more pharmaceutically acceptable excipients selected from diluent, binder, disintegrant, lubricant, glidant, surface active agent, stabilizing agent, sweetener and flavoring agent in which the formulation is effective for the prevention and/or treatment and/or supplementation of diseases associated with abnormal bone resorption and mentioned formulations increase the compliance of patient to treatment and thus the success of the treatment.
  • the term of "the use for the prevention and/or treatment and/or supplementation of disease and conditions associated with abnormal bone resorption" in the invention means in osteoporosis treatment; to reduce the risk of fracture in bones including vertebra and hip in the postmenopausal women; to reduce the risk of bone fractures in men in the treatment of osteoporosis; Idiopathis osteoporosis; various diseases caused by osteoporosis, and glucocorticoid and steroid mediated osteoporosis, osteopenia, osteomalacia, osteogenesis imperfecta, osteocondrodysplasia, Sudek's atrophy, rheumatoid arthritis, Paget's disease, malignant tumors of bone metastases, hypercalcaemia, or in the treatment of diseases such as hyperthyroidism; and nutritional supplements especially for woman which are in growth, pregnant or breast-feeding in the period before and after menopause to maintain bone health, but the explained usage areas are not limited with these.
  • a certain proportion and “optionally” mean that in order to obtain the desired therapeutic effect, preferred amount of alendronate ( or pharmaceutically acceptable salt, derivative or hydrate thereof) in the range of 0.1-980 mg, an amount of calcium salt( on the basis of elemental calcium) in the range of 250-5000 mg, an amount of vitamin D in the range of 100- 100000 IU and one or more pharmaceutically acceptable excipients to be used when necessary which are selected from a group of a diluent, binder, disintegrant, lubricant, glidant, surface active agent, sweetener and flavoring agent.
  • a pharmaceutically acceptable salt, derivative or hydrate of alendronate implies that salts can be selected from sodium, potassium, calcium, magnesium and ammonium salts; derivatives can be selected from ester and amide derivatives; hydrates can be selected from monohydrates, dihydrates, trihydrates, hemihydrates, 1 A hydrate, 1 A hydrate, % hydrate, % hydrate, V 4 hydrate, V 3 hydrate, V 2 hydrate and V 2 hydrate; preferably alendronate is alendronate monosodium trihydrate.
  • calcium salt implies that it can be selected from carbonate, chloride, citrate, glubionat, gluceptate, gluconate, lactate, phosphate, maleate, glycerophosphate, bicarbonate or tartarate salts.
  • the pharmaceutically acceptable diluents can be selected from a group consisting of lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and / or tribasic), calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, kaolin, lactilol, powdered cellulose, dextrose, dextares, dextrin, sucrose, maltose, fructose, mannitol, sorbitol, xylitol.
  • the diluent is present in the formulations preferably in the range of 0-85% by weight and more preferably 0.1-75% by weight.
  • the pharmaceutically acceptable binder can be selected from a group consisting of starch (potato starch, com starch, wheat starch, etc.). sugars such as sucrose, glucose, dextrose, lactose, maltodcxtrin, natural and synthetic gums (e.g. acacia), gelatin, cellulose derivatives (e.g. microcrystalline cellulose, HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose). polyvinylpyrollidone, polyethylene glycol, waxes, calcium carbonate, calcium phosphate, alcohols ( e.g. sorbitol, xylitol, mannitol) and water.
  • the binder is present in the formulations preferably in the range of 0-10% by weight and more preferably in the range of 0.1- 5% by weight.
  • the pharmaceutically acceptable disintegrants can be selected from a group consisting of starch (corn starch, potato starch), sodium starch glycolate, pregelatinized starch, cellulose derivatives (e.g. croscarmellose sodium or microcrystalline cellulose), polyvinylpyrollidone, crospovidone, alginic acid, sodium alginat, clays (e.g. xanthan gum or veegum), ion-exchange resins and effervescent systems (alkali or alkaline earth metal carbonates [e.g.
  • the disintegrant is present in the formulations preferably in the range of 0-85% by weight and more preferably in the range of 0.1-75% by weight.
  • Pharmaceutically acceptable lubricants can be selected from a group consisting of metallic stearates (magnesium stearate, calcium stearate, aluminum stearate, etc.), fatty acid esters (e.g. sodium stcaryl fumaratc), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenatc, mineral oil, paraffins, hydrogcnated vegetable oils, leucine, polyethylene glycols, metallic lauryl sulfates (sodium lauryl sulfate, magnesium lauryl sulfate, etc.), sodium chloride, sodium benzoate. sodium acetate and talk.
  • the lubricant is present in the formulations preferably in the range of 0-10% by weight and more preferably in the range of 0.1-5% by weight.
  • the pharmaceutical acceptable glidants can be selected from a group consisting of silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfate.
  • the glidant is found in a range below 1% by weight in the formulations.
  • the pharmaceutically acceptable surface active agents can be selected from a group consisting of polyoxyethylene-sorbitane-fatty acid esters (poiysorbates), sodium lauryl sulfate, sodium stearyl fumaratc, polyoxyethylcne alkyl ethers, sorbitane fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds. aminoacids like L-leucine, sugar esters of fatty acids, glycerides of fatty acids.
  • the surface active agent is present in the formulations preferably in the range of 0-10% by weight and more preferably in the range of 0.1 -5% by weight.
  • the stabilizing agent and/or agents can be selected from a group consisting of antioxidants, chelating agents, alkaline agents and photo-protectors.
  • the stabilization agent and/or agents is present in the formulations preferably in the range of 0-85% by weight and more preferably in the range of 0.1-75% by weight.
  • the antioxidants can be selected from a group consisting of butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulfite, gallates (e.g. propyl gallate), tocopherol, citric acid, malik acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbil palmitate, ethylenediamine tetraacetate.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • gallates e.g. propyl gallate
  • tocopherol citric acid, malik acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbil palmitate, ethylenediamine tetraacetate.
  • the chelating agents can be selected from a group consisting of disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
  • the alkalizing agents can be selected from a group consisting of sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen ortophosphate, alkali metal salts such as sodium aluminate; calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulfate, magnesium acetate, magnesium silicate, earth alkali metal salts like magnesium aluminate and primary, secondary and tertiary amines . , cyclic amines, organic compounds such as N-N'-dibenzylethylenediamine, diethanoleamine, ethylenediamine, meglumine, monosodium glucamate, polyacryline sodium, sodium alginate.
  • the photo-protector agents can be selected from a group consisting of metal oxides such as titanium oxide, iron oxide or zinc oxide.
  • the pharmaceutically acceptable sweeteners can be selected from a group consisting of sucralose, sucrose, fructose, glucose, galactose, xylose, dextrose, levulose, lactose, maltose, maltodextrin, mannitol, maltitol, maltol, sorbitol, xylitol, erytritol, lactitol, isomalt, com syrup, saccharin, saccharin salts, acesulphame potassium, aspartam, D-tryptophan, monoammonium glycerrizinate, neohesperidin dihydrochalcone, taumatine, neotam, alitam, steviosite and cyclamates.
  • the sweetener is present in the formulations preferably in the range of 0-5% by weight and more preferably in the range of 0.1-3% by weight.
  • the pharmaceutically acceptable flavoring agents can be selected from a group consisting of natural, aroma oils (peppermint oil, partridge currant oil, clove bud oil. parsley oil.
  • eucalyptus oil lemon oil, orange oil, etc.
  • menthol menthan
  • anetole methyl salicylate, ocaliptole, cinnamon, 1 -methyl acetate, ogenol, oxanone, alpha-irisone, marjoram, lemon, orange, propenyl guaetol acetyl, sinnamon, vanilla, timole, linalol, cinnamaldehyde glycerol acetal, N-substituted p-mentane-3-carboxyamide,3,l-methoxy propane 1,2-diol.
  • the flavoring agent is present in the formulations preferably in the range of 0-5% by weight and more preferably in the range of 0.1- 3% by weight.
  • compositions which are selected from resolution modulators, electrolytes, colorants and coating agents may be used in formulations.
  • the dosage form can be in the form of tablets, capsules, soluble tablets, fast-dissolving tablets, effervescent tablets, effervescent granules, fast-dissolving powder mixtures or dry powder mixture for preparation of syrup.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur une composition pharmaceutique stabilisée comprenant une combinaison d'agents actifs sous une forme posologique unique de façon à augmenter l'adaptation au patient et par conséquent le succès du traitement.
PCT/TR2010/000024 2009-02-05 2010-02-02 Composition pharmaceutique combinée sous une forme posologique unique WO2010090613A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2009/00880A TR200900880A2 (tr) 2009-02-05 2009-02-05 Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TR2009/00880 2009-02-05

Publications (1)

Publication Number Publication Date
WO2010090613A1 true WO2010090613A1 (fr) 2010-08-12

Family

ID=42040315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000024 WO2010090613A1 (fr) 2009-02-05 2010-02-02 Composition pharmaceutique combinée sous une forme posologique unique

Country Status (2)

Country Link
TR (1) TR200900880A2 (fr)
WO (1) WO2010090613A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093978A1 (fr) * 2011-01-06 2012-07-12 Mahmut Bilgic Formulations effervescentes de bisphosphonate
BE1019709A3 (fr) * 2010-12-22 2012-10-02 Calxx Laboratoires S A Produit alimentaire organo-mineral et procede de preparation.

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705651A (en) 1984-10-29 1987-11-10 Istituto Gentili S.P.A. Process for the preparation of diphosphonic acids
WO1999006051A1 (fr) 1997-07-30 1999-02-11 Menarini International Operations Luxembourg S.A. Compositions pharmaceutiques contenant de la vitamine d et du calcium, leur preparation et leur utilisation therapeutique
EP0969849B1 (fr) 1997-03-12 2003-07-23 MERCK PATENT GmbH Composition solide stable contenant de la vitamine d3 et du phosphate tricalcique
WO2003086415A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
EP0583378B1 (fr) 1991-05-06 2003-11-12 The Procter & Gamble Company Supplements combines de calcium et de vitamine d
WO2004022068A1 (fr) 2002-09-05 2004-03-18 Wisconsin Alumni Research Foundation Methode d'augmentation du dosage de composes a base de vitamine d
WO2004087038A1 (fr) * 2003-03-26 2004-10-14 The Procter & Gamble Company Trousse utilisable a des fins pharmaceutiques
WO2005027921A1 (fr) 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un bisphosphonate
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
CN1729995A (zh) * 2005-08-10 2006-02-08 石家庄制药集团欧意药业有限公司 一种防治骨质疏松、骨折的药物组合物及其应用
EP1651191A2 (fr) 2003-07-17 2006-05-03 Menarini International Operations Luxembourg S.A. Compositions pharmaceutiques effervescentes contenant de la vitamine d, du calcium et du phosphate et leur utilisation therapeutique

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705651A (en) 1984-10-29 1987-11-10 Istituto Gentili S.P.A. Process for the preparation of diphosphonic acids
EP0583378B1 (fr) 1991-05-06 2003-11-12 The Procter & Gamble Company Supplements combines de calcium et de vitamine d
EP0969849B1 (fr) 1997-03-12 2003-07-23 MERCK PATENT GmbH Composition solide stable contenant de la vitamine d3 et du phosphate tricalcique
WO1999006051A1 (fr) 1997-07-30 1999-02-11 Menarini International Operations Luxembourg S.A. Compositions pharmaceutiques contenant de la vitamine d et du calcium, leur preparation et leur utilisation therapeutique
WO2003086415A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
WO2004022068A1 (fr) 2002-09-05 2004-03-18 Wisconsin Alumni Research Foundation Methode d'augmentation du dosage de composes a base de vitamine d
WO2004087038A1 (fr) * 2003-03-26 2004-10-14 The Procter & Gamble Company Trousse utilisable a des fins pharmaceutiques
EP1651191A2 (fr) 2003-07-17 2006-05-03 Menarini International Operations Luxembourg S.A. Compositions pharmaceutiques effervescentes contenant de la vitamine d, du calcium et du phosphate et leur utilisation therapeutique
WO2005027921A1 (fr) 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un bisphosphonate
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
CN1729995A (zh) * 2005-08-10 2006-02-08 石家庄制药集团欧意药业有限公司 一种防治骨质疏松、骨折的药物组合物及其应用

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BLONDE L.: "Compliance and Persistence With Medication Therapy", MANAGED CARE, vol. 9, no. 9, 2000, Retrieved from the Internet <URL:who.int/icium/icium2004/resources/ppt/AC016.ppt.>
BRAZIER M ET AL: "BIOLOGICAL EFFECTS OF SUPPLEMENTATION WITH VITAMIN D AND CALCIUM IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS RECEIVING ALENDRONATE", CLINICAL DRUG INVESTIGATION, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 22, no. 12, 1 January 2002 (2002-01-01), pages 849 - 857, XP008033378, ISSN: 1173-2563 *
CHAPUY M. C.: "Vitamin D3 and calcium to prevent hip fractures in elderly women", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 327, 1992, pages 1637 - 42
DATABASE WPI Week 200649, Derwent World Patents Index; AN 2006-472934, XP002576493 *
HO A.; KUNG A.: "Efficacy and Tolerability of Alendronate Once Weekly in Asian Postmenopausal Osteoporotic Women", THE ANNALS OF PHARMACOTHERAPY, vol. 39, no. 9, pages 1428 - 1433
MCCOMSEY G. A. ET AL.: "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV", AIDS, vol. 21, no. 18, 2007, pages 2473 - 82
MERCK & CO., INC.: "Fosamax Plus D", 2005, XP002576495, Retrieved from the Internet <URL:www.fosamax.com> [retrieved on 20100406] *
MONDY K, POWDERLY W G, CLAXTON S A, YARASHESKI K H, ROYAL M, STONEMAN J S, HOFFMANN M E, TEBAS P: "Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection", JAIDS JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, vol. 38, no. 4, 1 April 2005 (2005-04-01), pages 426 - 431, XP002576494 *
MONDY K.: "Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection", J ACQUIR IMMUNE DEFIC SYNDR., vol. 38, no. 4, 2005, pages 426 - 31
RECKER R.: "Alendronate with and without cholecalciferol for osteoporosis: results of a 15- week randomized controlled trial", CURR MED RES OPIN., vol. 22, no. 9, 2006, pages 1745 - 55
SABAT6, E.: "Adherence to Long term Therapies: Evidence for Action", WORLD HEALTH ORGANIZATION, 2003, pages 212

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1019709A3 (fr) * 2010-12-22 2012-10-02 Calxx Laboratoires S A Produit alimentaire organo-mineral et procede de preparation.
WO2012093978A1 (fr) * 2011-01-06 2012-07-12 Mahmut Bilgic Formulations effervescentes de bisphosphonate

Also Published As

Publication number Publication date
TR200900880A2 (tr) 2010-08-23

Similar Documents

Publication Publication Date Title
WO2010090614A1 (fr) Formulation pharmaceutique comprenant du risédronate, du carbonate de calcium et de la vitamine d3 combinés en une forme posologique unique
KR100893847B1 (ko) 칼슘-함유 화합물을 활성 물질로서 함유하는 씹어먹거나흡입 및 삼킬 수 있는 태블릿
US20070104786A1 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
AU2005256317B2 (en) Compositions comprising strontium and vitamin D and uses thereof
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
RU2405541C2 (ru) Фармацевтические композиции, рассасывающиеся в ротовой полости
JP2005531532A (ja) アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
WO2010101537A1 (fr) Composition pharmaceutique de principes actifs combinés en forme posologique unique
KR20070043714A (ko) 칼슘-함유 화합물 및 당알코올을 포함하는 입상체
EP2496222B1 (fr) Compositions pharmaceutiques comprenant du calcium et de la vitamine d
JP2014205711A (ja) ビタミンｄ誘導体の前用量投与によってアレンドロネート等のビスフォスフォネートの生体利用効率を高める方法
WO2011152810A1 (fr) Formulations comprenant du calcium, de la vitamine d et de la vitamine k pour traiter l&#39;ostéoporose
WO2010008976A2 (fr) Compléments combinés de calcium, magnésium et vitamine d
EP2575758A1 (fr) Formulation pour l&#39;ostéoporose
ES2192136B1 (es) Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
EP2393516B1 (fr) Compositions pharmaceutiques stables, à goût et odeur masqués comprenant de la n-acétylcystéine et de la vitamine c
WO2010090613A1 (fr) Composition pharmaceutique combinée sous une forme posologique unique
JP2009508834A (ja) ビスホスホネート製剤
WO2011113965A1 (fr) Composition pharmaceutique sous forme solide contenant des isoflavones, un sel de calcium et de la vitamine d3
ES2343294B1 (es) Composicion farmaceutica en forma solida que contiene isoflavonas, una sal de calcio y vitamina d3.
WO2012093974A1 (fr) Formulations améliorées de bisphosphonates
MXPA97004105A (en) Set for use in a therapeutic treatment cycle of osteoporo
WO2012093976A1 (fr) Composition comportant de l&#39;ibandronate, au moins 50 % d&#39;un agent de charge et un agent édulcorant
WO2012093977A1 (fr) Formulations pharmaceutiques hydrosolubles comprenant de l&#39;ibandronate et un sel inorganique, destinées à être utilisées dans le traitement de maladies osseuses
WO2012093980A1 (fr) Formulation améliorée à base de risédronate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10705013

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10705013

Country of ref document: EP

Kind code of ref document: A1